Open Access
Article

ARID1A-mutated cervical cancer depends on the activation of YAP signaling

Fei Gao1,Peiling Li1,*,Xianchao Kong1,Tiefang Song1,Qi Han1,Suiyang Zhou1
1
Department of Obstetrics and Gynecology, The 2nd Affiliated Hospital of Harbin Medical University, 150081 Harbin, Heilongjiang, China
DOI: 10.52586/5035 Volume 26 Issue 12, pp.1411-1421
Submited: 12 August 2021 Revised: 09 December 2021
Accepted: 10 December 2021 Published: 30 December 2021
*Corresponding Author(s):  
Peiling Li
E-mail:  
pl0902hz@163.com
Copyright: © 2021 The author(s). Published by BRI. This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract

Background: Cervical cancer is a prevalent female malignancy with poor survival rates. ARID1A is frequently mutated or deleted in a variety of tumors and YAP signaling is widely activated in human malignancies. Nevertheless, the mechanism of YAP signaling in ARID1A-mutated cervical cancer remains unknown. Methods: The cell viability was determined by MTT assay. The expression of ARID1A, YAP1 and CTGF were evaluated by western blot. The cell proliferation was detected by colony formation. Results: The bioinformatics analysis suggested that mutation of ARID1A was associated with the activation of YAP1 signaling. In addition, knockdown of YAP1 inhibited ARID1A-mutated cervical cancer cells growth. Verteporfin is an inhibition of YAP1 signaling. Interestingly, knockdown of ARID1A decreased ARID1A-wildtype cervical cancer cells resistance to verteporfin. Meanwhile, overexpression of ARID1A increased ARID1A-mutated cervical cancer cells resistance to verteporfin. Similarly, blocking YAP1 signaling inhibited the tumor formation caused by ARID1A-mutated cervical cancer cells in vivo. Conclusion: Inhibition of YAP1 signaling suppresses ARID1A-mutated-induced tumorigenesis of cervical cancer, providing a novel therapeutic strategy for cervical cancer.

Key words

Cervical cancer; ARID1A; Proliferation; YAP signaling

References

[1] Marth C, Landoni F, Mahner S, McCormack M, Gonzalez-Martin A, Colombo N, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017; 28: iv72–iv83.

[2] Zhao S, Yan L, Zhao Z, Rong F. Up-regulation of miR-203 inhibits the growth of cervical cancer cells by inducing cell cycle arrest and apoptosis. European Journal of Gynaecological Oncology. 2019; 40: 791–795.

[3] Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Lifeyears for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology. 2017; 3: 524–548.

[4] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer. 2015; 136: E359–E386.

[5] Arab M, Moridi A, Fazli G, Ghodssi-Ghassemabadi R, Sanati M. Is visual inspection with acetic acid (VIA) a useful method of finding pre-invasive cervical cancer? Clinical and Experimental Obstetrics & Gynecology. 2021; 48: 128–131.

[6] Tian JDC, Liang L. Involvement of circular RNA SMARCA5/microRNA-620 axis in the regulation of cervical cancer cell proliferation, invasion and migration. European review for medical and pharmacological sciences. 2018; 22: 8589–8598.

[7] Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: A cancer Journal for Clinicians. 2013; 63: 11–30.

[8] Mathur R. ARID1a loss in cancer: towards a mechanistic understanding. Pharmacology & Therapeutics. 2018; 190: 15–23.

[9] Bitler BG, Aird KM, Garipov A, Li H, Amatangelo M, Kossenkov AV, et al. Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1a-mutated cancers. Nature Medicine. 2015; 21: 231–238.

[10] Chang L, Azzolin L, Di Biagio D, Zanconato F, Battilana G, Lucon Xiccato R, et al. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ. Nature. 2018; 563: 265–269.

[11] Piccolo S, Dupont S, Cordenonsi M. The Biology of YAP/TAZ: Hippo Signaling and beyond. Physiological Reviews. 2014; 94: 1287–1312.

[12] Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016; 29: 783–803.

[13] Burk RD, Chen Z, Saller C, Tarvin K, Carvalho AL, Scapulatempo-Neto C, et al. Integrated genomic and molecular characterization of cervical cancer. Nature. 2017; 543: 378–384.

[14] Wang X, Nagl NG, Flowers S, Zweitzig D, Dallas PB, Moran E. Expression of p270 (ARID1a), a component of human SWI/SNF complexes, in human tumors. International Journal of Cancer. 2004; 112: 636.

[15] Zhou Y, Zhang J, Li H, Huang T, Wong CC, Wu F, et al. AMOTL1 enhances YAP1 stability and promotes YAP1-driven gastric oncogenesis. Oncogene. 2020; 39: 4375–4389.

[16] Brodowska K, Al-Moujahed A, Marmalidou A, Meyer Zu Horste M, Cichy J, Miller JW, et al. The clinically used photosensitizer Verteporfin (VP) inhibits YAP-TEAD and human retinoblastoma cell growth in vitro without light activation. Experimental Eye Research. 2014; 124: 67–73.

[17] Marquina G, Manzano A, Casado A. Targeted Agents in Cervical Cancer: beyond Bevacizumab. Current Oncology Reports. 2018; 20: 40.

[18] Takeda T, Banno K, Okawa R, Yanokura M, Iijima M, Irie-Kunitomi H, et al. ARID1a gene mutation in ovarian and endometrial cancers (Review). Oncology Reports. 2016; 35: 607–613.

[19] Kimura Y, Fukuda A, Ogawa S, Maruno T, Takada Y, Tsuda M, et al. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice. Gastroenterology. 2018; 155: 194–209.e2.

[20] Ye S, Yang J, You Y, Cao D, Huang H, Wu M, et al. Clinicopathologic Significance of HNF-1beta, AIRD1A, and PIK3CA Expression in Ovarian Clear Cell Carcinoma: A Tissue Microarray Study of 130 Cases. Medicine. 2016; 95: e3003.

[21] Inada R, Sekine S, Taniguchi H, Tsuda H, Katai H, Fujiwara T, et al. ARID1a expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status. World Journal of Gastroenterology. 2015; 21: 2159–2168.

[22] Yang Y, Wang X, Yang J, Duan J, Wu Z, Yang F, et al. Loss of ARID1a promotes proliferation, migration and invasion via the Akt signaling pathway in NPC. Cancer Management and Research. 2019; 11: 4931–4946.

[23] Sun X, Chuang J, Kanchwala M, Wu L, Celen C, Li L, et al. Suppression of the SWI/SNF Component Arid1a Promotes Mammalian Regeneration. Cell Stem Cell. 2016; 18: 456–466.

[24] Bitler BG, Wu S, Park PH, Hai Y, Aird KM, Wang Y, et al. ARID1a-mutated ovarian cancers depend on HDAC6 activity. Nature Cell Biology. 2017; 19: 962–973.

[25] Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Science Signaling. 2013; 6: pl1.

[26] Nguyen CDK, Yi C. YAP/TAZ Signaling and Resistance to Cancer Therapy. Trends in Cancer. 2019; 5: 283–296.

[27] He C, Mao D, Hua G, Lv X, Chen X, Angeletti PC, et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Molecular Medicine. 2015; 7: 1426–1449.

[28] Morgan EL, Patterson MR, Ryder EL, Lee SY, Wasson CW, Harper KL, et al. MicroRNA-18a targeting of the STK4/MST1 tumour suppressor is necessary for transformation in HPV positive cervical cancer. PLoS Pathogens. 2020; 16: e1008624.

[29] Nishio M, To Y, Maehama T, Aono Y, Otani J, Hikasa H, et al. Endogenous YAP1 activation drives immediate onset of cervical carcinoma in situ in mice. Cancer Science. 2020; 111: 3576–3587.

[30] Wang C, Davis JS. At the center of cervical carcinogenesis: synergism between high-risk HPV and the hyperactivated YAP1. Molecular & Cellular Oncology. 2019; 6: e1612677.

[31] Park J, Eisenbarth D, Choi W, Kim H, Choi C, Lee D, et al. YAP and AP-1 Cooperate to Initiate Pancreatic Cancer Development from Ductal Cells in Mice. Cancer research. 2020; 80: 4768–4779.

[32] Ni X, Tao J, Barbi J, Chen Q, Park BV, Li Z, et al. YAP is Essential for Treg-Mediated Suppression of Antitumor Immunity. Cancer Discovery. 2018; 8: 1026–1043.

[33] Zhao J, Li L, Yang T. MiR-216a-3p suppresses the proliferation and invasion of cervical cancer through downregulation of ACTL6a-mediated YAP signaling. Journal of Cellular Physiology. 2020; 235: 9718–9728.

[34] Yang F, Li L, Zhang J, Zhang J, Yang L. TRIP6 accelerates the proliferation and invasion of cervical cancer by upregulating oncogenic YAP signaling. Experimental Cell Research. 2020; 396: 112248.

[35] Zhang J, Zhao X, Zhang J, Zheng X, Li F. Circular RNA hsa_circ_0023404 exerts an oncogenic role in cervical cancer through regulating miR-136/TFCP2/YAP pathway. Biochemical and Biophysical Research Communications. 2018; 501: 428–433.

[36] Wang M, Liu C, Li Y, Zhang Q, Zhu L, Fang Z, et al. Verteporfin Is a Promising Anti-Tumor Agent for Cervical Carcinoma by Targeting Endoplasmic Reticulum Stress Pathway. Frontiers in Oncology. 2020; 10: 1781.

Share and Cite
Fei Gao, Peiling Li, Xianchao Kong, Tiefang Song, Qi Han, Suiyang Zhou. ARID1A-mutated cervical cancer depends on the activation of YAP signaling. Frontiers in Bioscience-Landmark. 2021. 26(12); 1411-1421.